Article

Precision Neoantigen Discovery Using Large-scale Immunopeptidomes and Composite Modeling of MHC Peptide Presentation Immunopeptidomics Special Issue of the journal Molecular & Cellular Proteomics January 2021 Volume 20, 100111 The Personalis authors created Systematic HLA Epitope Ranking Pan Algorithm (SHERPA™), a novel pan-allelic machine learning algorithm for predicting MHC-peptide binding and [...]

Prediction of Immunotherapy Response in Melanoma through Combined Modeling of Neoantigen Burden and Immune-Related Resistance Mechanisms Clinical Cancer Research August 2021 Volume 27, Issue 15 This work evaluates the predictive strength of a composite biomarker, neoantigen presentation score (NEOPS), in a cohort of patients with late-stage melanoma. NEOPS incorporates damaging events [...]

An Empirical Antigen Selection Method Identifies Neoantigens That Either Elicit Broad Antitumor T-cell Responses or Drive Tumor Growth. Cancer Discovery March 2021  Hubert Lam et al. View Publication View PDF

CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study. The Lancet Oncology January 2021  O'Hara, Mark H et al. View Publication

Whole-exome sequencing based immunogenomic profiling with potential clinical applicability in circulating cell-free DNA and tissue from advanced stage colorectal cancer patients. Journal for ImmunoTherapy of Cancer  November 2020 Feng Z, Scheuenpflug J, Tan M et al. View Publication View PDF

A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer. Cell October 2020  Ott, Patrick A et al. View Publication

Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial. Nature Medicine September 7, 2020 Motzer, RJ, Robbins, PB, Powles, T et al. View Publication View PDF

Safety and activity of ibrutinib in combination with durvalumab in patients with relapsed or refractory follicular lymphoma or diffuse large B-cell lymphoma. American Journal of Hematology January 2020  Herrera AF, Goy A, Mehta A et al. View Publication View PDF

Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study. The Lancet Gastroenterology & Hepatology September 1, 2019  Lowery, Maeve A et al. View Publication

Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial. The Lancet Oncology December 9, 2016  Dimopoulos, Meletios A et al. View Publication